SJP supplementation reduced the fasting glucose (Figure 5E, p < 0.05) and fasting insulin (Figure 5F, p < 0.05) levels and ameliorated serum hyperlipidemia with a reduction in the levels of TC (Figure 5I, p < 0.05), TG (Figure 5J, p < 0.05), and LDLC (Figure 5K, p < 0.05) in HFD-fed mice. The gene discussed is INS; the disease is hyperlipidemia.